Cargando…
Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma
Clinical trials involving anti-programmed cell death protein-1 (anti-PD-1) failed to demonstrate improved overall survival in glioblastoma (GBM) patients. This may be due to the expression of alternative checkpoints such as B- and T- lymphocyte attenuator (BTLA) on several immune cell types includin...
Autores principales: | Choi, John, Medikonda, Ravi, Saleh, Laura, Kim, Timothy, Pant, Ayush, Srivastava, Siddhartha, Kim, Young-Hoon, Jackson, Christina, Tong, Luqing, Routkevitch, Denis, Jackson, Christopher, Mathios, Dimitrios, Zhao, Tianna, Cho, Hyerim, Brem, Henry, Lim, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409779/ https://www.ncbi.nlm.nih.gov/pubmed/34484870 http://dx.doi.org/10.1080/2162402X.2021.1956142 |
Ejemplares similares
-
Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma
por: Choi, John, et al.
Publicado: (2021) -
Alternative Checkpoints as Targets for Immunotherapy
por: Pant, Ayush, et al.
Publicado: (2020) -
Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors
por: Nicholas, Sarah, et al.
Publicado: (2013) -
BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
por: Battin, Claire, et al.
Publicado: (2022) -
ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma
por: Tong, Luqing, et al.
Publicado: (2020)